For many people with large B-cell lymphoma, the fear of relapse never really goes away. Allogene’s new ALPHA3 trial is looking to change that by exploring a therapy designed to help more patients stay cancer-free. Our own Dr. Zachary J Roberts MD PhD joined Katie Couric to discuss what this approach could mean for the future of cancer treatment. Watch the full episode: https://lnkd.in/g9P8vDZR
About us
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
- Website
- www.allogene.com
External link for Allogene Therapeutics
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2017
- Specialties
- oncology, cancer, biotechnology, immunotherapy, CAR T, and autoimmune
Locations
- Primary Get directions
210 E Grand Ave
South San Francisco, California 94080, US
- Get directions
7400 Gateway Blvd
Newark, California 94560, US
Employees at Allogene Therapeutics
Updates
-
A new 1L consolidation approach is being studied to help predict and potentially prevent relapse in LBCL patients following frontline therapy. Learn more about the ALPHA3 clinical trial and its potential to revolutionize patient care. #LBCL #CART #celltherapy #allogeneic Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar
-
-
Join us for an exclusive session with David Kurtz, Chief Medical Officer at Foresight Diagnostics, who will present an overview of the ALPHA3 trial, a pivotal Phase 2 study evaluating cema-cel, our investigational allogeneic CAR T therapy, as consolidation for MRD+ #LBCL patients. Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar
-
-
Congrats to the Foresight Diagnostics team! This is validation of the transformative potential of #MRD testing, with a leader like Natera recognizing its value. It also strengthens our diagnostic partner as we look beyond ALPHA3 toward potential commercialization for cema-cel. Allogene has long believed MRD would become central to treatment decisions, and the ALPHA3 design reflects where the field is now headed.
Today, we are pleased to announce that Foresight Diagnostics is now part of Natera, uniting Natera’s best-in-class precision diagnostics portfolio and commercial and operational infrastructure with our innovative phased-variant ctDNA-MRD technology and lymphoma leadership. Since our founding, our mission has always been to improve the lives of cancer patients worldwide through innovative diagnostics. Together with Natera, we can realize this mission on a far greater scale, accelerating the pace of discovery across both hematologic and solid tumors. We are deeply grateful to our employees, partners, and investors who have helped bring us to this moment! Read the press release here: https://lnkd.in/eadEPWHX
-
-
Our allogeneic CAR-T platform aims to reshape treatment for large B-cell lymphoma - offering a scalable, "off-the-shelf" innovation to reach more patients, faster. Proud to see our work highlighted in Nature. Learn More: https://lnkd.in/gKR5QrYN
-
-
Proud to showcase our pivotal Phase 2 ALPHA3 study with a Trial-in-Progress poster at #ASH25. ALPHA3 is designed to explore the potential of "off-the-shelf" #CAR T therapy as first-line consolidation for patients with #LBCL. Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar
-
-
LBCL patients face the fear of relapse after treatment ends. Our ALPHA3 trial is working to change that by testing a therapy aimed at preventing cancer from returning. Dr. Zachary Roberts joined Katie Couric to discuss the science behind this new approach. Watch the full episode: https://lnkd.in/g9P8vDZR
-
-
1 in 3 LBCL patients will see their cancer return after 1L treatment. Discover how the ALPHA3 trial design combines investigational minimal residual disease (MRD) testing technology and an “off-the-shelf” CAR T product to intervene early and potentially improve cure rates. #LBCL #CART #celltherapy #allogeneic Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar
-
-
We’re pleased to participate in the 37th Annual Piper Sandler Healthcare Conference tomorrow where our CEO and Co-Founder David Chang will share insights on our pipeline and corporate strategy. #CART Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar
-
-
At Allogene, we're advancing CAR T therapy to transform lives. Through bold innovation in cell therapy, we’re working to expand access and redefine what’s possible for patients. Follow us to learn more about the latest breakthroughs. #CART #celltherapy #allogeneic Learn More: Allogene.com/Home
-